- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07736885
Evaluation of Clinical Efficacy and Mechanism of Hand Jing-Well Acupoint Transcutaneous Electrical Stimulation in Improving Post-Stroke Cognitive Impairment
This study evaluates a non-invasive electrical stimulation therapy applied to specific acupoints on the fingers (called Jing-Well points) to improve thinking and memory problems after stroke.
Purpose: Many stroke survivors develop cognitive difficulties (problems with memory, attention, and decision-making). Current treatments are limited. This study tests whether gentle electrical stimulation to hand acupoints can improve these symptoms.
Who can participate: Adults aged [35-80] who have had an ischemic stroke and now have mild to moderate cognitive impairment.
What happens: Participants will be randomly assigned to receive either (1) active electrical stimulation to hand Jing-Well points, (2) sham (fake) stimulation. Treatment will last 4 weeks, 6 sessions per week, each 30 minutes, with a stimulation frequency of 10 Hz and intensity adjusted to each participant's tolerance. Cognitive tests and brain imaging will be done before and after treatment.
Potential benefits: Participants may experience improved cognitive function. The study will also help researchers understand how this therapy works in the brain.
Risks: The electrical stimulation may cause mild tingling or skin irritation at the electrode sites. Brain imaging is non-invasive and safe. All procedures will be performed by trained professionals.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Liang Gao
- Número de telefone: 8618722216295
- E-mail: Gaoliang202605@163.com
Locais de estudo
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300073
- Recrutamento
- The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
-
Contato:
- Liang Gao
- Número de telefone: 8618722216295
- E-mail: Gaoliang202605@163.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Aged 35-80 years;
- Stroke duration within 2 weeks to 6 months post-onset;
- Cognitive impairment confirmed by neuropsychological assessment: Montreal Cognitive Assessment (MoCA) score < 26;
- Clinical evaluation excludes delirium, major depressive disorder, schizophrenia, or other primary psychiatric/behavioral disorders as the principal cause of current cognitive impairment. No history of other known neurological diseases that may cause cognitive impairment (e.g., multiple sclerosis, encephalitis, Parkinson's disease, post-traumatic dementia, normal pressure hydrocephalus, etc.);
- No severe aphasia; able to cooperate with scale assessments and complete the treatment protocol required by this study;
- Voluntary participation in this study; the participant or their legally authorized representative has signed the informed consent form.
Exclusion Criteria:
- Unstable vital signs or life-threatening comorbidities;
- Implanted devices (cardiac pacemaker/defibrillator, deep brain stimulator, etc.);
- History of epilepsy or epileptic seizures;
- Pregnant or lactating women;
- Concurrent use of other medications affecting cognitive function;
- Allergy to the study intervention device or history of serious adverse reactions;
- Severe arrhythmia, malignant hypertension, or severe dysfunction of vital organs (heart, liver, kidney, etc.);
- Individuals unable to participate in treatment due to severe hearing or visual impairment, or bilateral limb paralysis.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Active TES Group
Participants receive transcutaneous electrical stimulation at hand Jing-Well acupoints (Shaoze SI1, Shangyang LI1, Zhongchong PC9, Guanchong SJ1, Shaochong HT9, and Dadun LR1) using a portable stimulator.
Stimulation parameters: 10 Hz square wave, pulse width 320 μs, intensity adjusted to individual tolerance (typically 0-1 mA), 30 minutes per session, 6 sessions per week for 4 consecutive weeks (24 sessions total).
|
Device-based transcutaneous electrical stimulation (TES) delivered to six hand Jing-Well acupoints: Shaoze (SI1), Shangyang (LI1), Zhongchong (PC9), Guanchong (SJ1), Shaochong (HT9), and Dadun (LR1).
A custom-designed portable electrical stimulator (model YM-JX-V01, manufactured by Yimai Artificial Intelligence Medical Technology (Tianjin) Co., Ltd.) is used with disposable self-adhesive reference electrodes (4 × 4 cm) and stimulation electrodes (diameter 5 mm).
Stimulation parameters: square wave, frequency 10 Hz, pulse width 320 μs, intensity individually titrated to sensory threshold (typically 0-1 mA), session duration 30 minutes.
Treatment schedule: 6 sessions per week (Monday-Saturday) for 4 consecutive weeks, totaling 24 sessions.
Electrodes are placed bilaterally at the designated acupoints according to WHO Standard Acupuncture Point Locations.
|
|
Comparador Falso: Sham TES Group
Participants receive sham transcutaneous electrical stimulation at hand Jing-Well acupoint locations using an identical-appearing device with the same electrode placement pattern as the active group.
The device delivers ineffective stimulation (0 Hz, no current output) while maintaining identical visual and tactile feedback.
Sessions follow the same schedule as the active group: 30 minutes per session, 6 sessions per week for 4 consecutive weeks (24 sessions total).
|
Device-based sham transcutaneous electrical stimulation (TES) delivered to six hand Jing-Well acupoints: Shaoze (SI1), Shangyang (LI1), Zhongchong (PC9), Guanchong (SJ1), Shaochong (HT9), and Dadun (LR1).
A custom-designed portable electrical stimulator with open-circuit design (model YM-JX-V01, manufactured by Yimai Artificial Intelligence Medical Technology (Tianjin) Co., Ltd.) is used with disposable self-adhesive reference electrodes (4 × 4 cm) and stimulation electrodes (diameter 5 mm).
The device delivers ineffective stimulation (0 Hz, no current output) while maintaining identical visual and tactile feedback.
Sessions follow the same schedule as the active group: 30 minutes per session, 6 sessions per week for 4 consecutive weeks (24 sessions total).
Electrodes are placed bilaterally at the designated acupoints according to WHO Standard Acupuncture Point Locations.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
MoCA(Montreal Cognitive Assessment)
Prazo: From enrollment to the end of treatment at 4 weeks
|
From enrollment to the end of treatment at 4 weeks
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
Mini-Mental State Examination(MMSE)
Prazo: From enrollment to the end of treatment at 4 weeks
|
From enrollment to the end of treatment at 4 weeks
|
|
Vascular Dementia Assessment Scale-cognitive subscale(VaDAS-cog )
Prazo: From enrollment to the end of treatment at 4 weeks
|
From enrollment to the end of treatment at 4 weeks
|
|
Activities of Daily Living Scale(ADL)
Prazo: From enrollment to the end of treatment at 4 weeks
|
From enrollment to the end of treatment at 4 weeks
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Whole-brain frequency band absolute and relative power derived from resting-state electroencephalography (EEG)
Prazo: From enrollment to the end of treatment at 4 weeks
|
Resting-state EEG signals will be acquired.
Absolute power and relative power of multiple frequency bands (delta, theta, alpha, beta) across the whole brain will be quantified to reflect cortical electrical activity.
|
From enrollment to the end of treatment at 4 weeks
|
|
Concentration changes of oxygenated hemoglobin (HbO) and deoxygenated hemoglobin (HbR) measured by functional near-infrared spectroscopy (fNIRS)
Prazo: From enrollment to the end of treatment at 4 weeks
|
Prefrontal cortical hemodynamic signals will be acquired via resting-state functional near-infrared spectroscopy.
Concentration changes of oxygenated hemoglobin (HbO) and deoxygenated hemoglobin (HbR) will be quantified to evaluate cerebral hemodynamic function.
|
From enrollment to the end of treatment at 4 weeks
|
|
C-Reactive Protein
Prazo: From enrollment to the end of treatment at 4 weeks
|
From enrollment to the end of treatment at 4 weeks
|
|
|
Folic Acid / Folate
Prazo: From enrollment to the end of treatment at 4 weeks
|
From enrollment to the end of treatment at 4 weeks
|
|
|
Homocysteine(Hcy)
Prazo: From enrollment to the end of treatment at 4 weeks
|
From enrollment to the end of treatment at 4 weeks
|
|
|
Vitamin B12 / Cobalamin
Prazo: From enrollment to the end of treatment at 4 weeks
|
From enrollment to the end of treatment at 4 weeks
|
Colaboradores e Investigadores
Publicações e links úteis
Publicações Gerais
- Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, Hatsukami TS, Higashida RT, Johnston SC, Kidwell CS, Lutsep HL, Miller E, Sacco RL; American Heart Association; American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Interdisciplinary Council on Peripheral Vascular Disease. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke. 2009 Jun;40(6):2276-93. doi: 10.1161/STROKEAHA.108.192218. Epub 2009 May 7.
- Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, Elkind MS, George MG, Hamdan AD, Higashida RT, Hoh BL, Janis LS, Kase CS, Kleindorfer DO, Lee JM, Moseley ME, Peterson ED, Turan TN, Valderrama AL, Vinters HV; American Heart Association Stroke Council, Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; Council on Peripheral Vascular Disease; Council on Nutrition, Physical Activity and Metabolism. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013 Jul;44(7):2064-89. doi: 10.1161/STR.0b013e318296aeca. Epub 2013 May 7.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- TYLL2026-K-076
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .